Several studies have reported that the aberrant expression of FNDC3B has been observed in various cancers, acting as a potential biomarker (Katoh et al. 2015; Fucci et al. 2020; Han et al. 2020), as well as in the brain tissue of patients with epilepsy and brain tumors (Kwon et al. 2023). The gene discussed is FNDC3B; the disease is cancer.